147 related articles for article (PubMed ID: 12654696)
1. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.
Selleseth DW; Talarico CL; Miller T; Lutz MW; Biron KK; Harvey RJ
Antimicrob Agents Chemother; 2003 Apr; 47(4):1468-71. PubMed ID: 12654696
[TBL] [Abstract][Full Text] [Related]
2. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.
Evers DL; Komazin G; Shin D; Hwang DD; Townsend LB; Drach JC
Antiviral Res; 2002 Oct; 56(1):61-72. PubMed ID: 12323400
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.
Biron KK; Harvey RJ; Chamberlain SC; Good SS; Smith AA; Davis MG; Talarico CL; Miller WH; Ferris R; Dornsife RE; Stanat SC; Drach JC; Townsend LB; Koszalka GW
Antimicrob Agents Chemother; 2002 Aug; 46(8):2365-72. PubMed ID: 12121906
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.
McSharry JJ; McDonough A; Olson B; Talarico C; Davis M; Biron KK
Clin Diagn Lab Immunol; 2001 Nov; 8(6):1279-81. PubMed ID: 11687477
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
6. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
Chou S; Marousek GI
Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.
Williams SL; Hartline CB; Kushner NL; Harden EA; Bidanset DJ; Drach JC; Townsend LB; Underwood MR; Biron KK; Kern ER
Antimicrob Agents Chemother; 2003 Jul; 47(7):2186-92. PubMed ID: 12821466
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
Reitsma JM; Terhune SS
Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
Zacny VL; Gershburg E; Davis MG; Biron KK; Pagano JS
J Virol; 1999 Sep; 73(9):7271-7. PubMed ID: 10438815
[TBL] [Abstract][Full Text] [Related]
11. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.
McGregor A; Choi KY; Cui X; McVoy MA; Schleiss MR
Antiviral Res; 2008 Jun; 78(3):250-9. PubMed ID: 18325607
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94).
Chan JH; Chamberlain SD; Biron KK; Davis MG; Harvey RJ; Selleseth DW; Dornsife RE; Dark EH; Frick LW; Townsend LB; Drach JC; Koszalka GW
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):101-23. PubMed ID: 10772705
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.
Chou S; Ercolani RJ; Derakhchan K
Antiviral Res; 2018 Sep; 157():128-133. PubMed ID: 30040968
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.
Evers DL; Komazin G; Ptak RG; Shin D; Emmer BT; Townsend LB; Drach JC
Antimicrob Agents Chemother; 2004 Oct; 48(10):3918-27. PubMed ID: 15388453
[TBL] [Abstract][Full Text] [Related]
15. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.
Underwood MR; Ferris RG; Selleseth DW; Davis MG; Drach JC; Townsend LB; Biron KK; Boyd FL
Antimicrob Agents Chemother; 2004 May; 48(5):1647-51. PubMed ID: 15105116
[TBL] [Abstract][Full Text] [Related]
17. Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.
Snoeck R; Andrei G; Schols D; Balzarini J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1144-55. PubMed ID: 1337893
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.
Underwood MR; Harvey RJ; Stanat SC; Hemphill ML; Miller T; Drach JC; Townsend LB; Biron KK
J Virol; 1998 Jan; 72(1):717-25. PubMed ID: 9420278
[TBL] [Abstract][Full Text] [Related]
19. Impact of RNA polymerase I inhibitor CX-5461 on viral kinase-dependent and -independent cytomegalovirus replication.
Westdorp KN; Terhune SS
Antiviral Res; 2018 May; 153():33-38. PubMed ID: 29458130
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs).
Wild M; Kicuntod J; Seyler L; Wangen C; Bertzbach LD; Conradie AM; Kaufer BB; Wagner S; Michel D; Eickhoff J; Tsogoeva SB; Bäuerle T; Hahn F; Marschall M
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
